FDA guidance on formal meetings adds new categories, timelines
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyPharmaceuticalsRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyPharmaceuticals